Since high-grade Neuroblastoma, which are largely therapy resistant, are often characterized by Caspase-8 deficiency, we aimed to investigate whether TLR3 can induce an alternative programmed cell death pathway in the absence of Caspase-8. This evidence concerns the gene CASP8 and neuroblastoma.